Investors are closely watching FDA approved Tirzepatide manufacturer Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Analysts are expecting strong performance driven by the robust sales of Lilly's blockbuster drugs, particularly recent launches. However, there are also concerns